Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 25 Hydroxycholecalciferol
2. 25 Hydroxycholecalciferol Monohydrate
3. 25 Hydroxyvitamin D 3
4. 25 Hydroxyvitamin D3
5. 25-hydroxycholecalciferol
6. 25-hydroxycholecalciferol Monohydrate
7. 25-hydroxyvitamin D 3
8. 25-hydroxyvitamin D3
9. Anhydrous, Calcifediol
10. Calcidiol
11. Calcifediol Anhydrous
12. Calcifediol, (3 Alpha,5z,7e)-isomer
13. Calcifediol, (3 Beta,5e,7e)-isomer
14. Calderol
15. Dedrogyl
16. Hidroferol
17. Monohydrate, 25-hydroxycholecalciferol
1. Calcidiol
2. 25-hydroxyvitamin D3
3. 19356-17-3
4. 25-hydroxycholecalciferol
5. Calcifediol Anhydrous
6. Hidroferol
7. 25-hydroxyvitamin D
8. Calderol
9. Didrogyl
10. Calcifediolum
11. Rayaldee
12. Ro 8-8892
13. 5,6-cis-25-hydroxyvitamin D3
14. Calcifediol [inn]
15. Cholecalciferol, 25-hydroxy-
16. Chebi:17933
17. (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol
18. T0wxw8f54e
19. 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
20. Ncgc00161326-04
21. Calcifidiol
22. Delakmin
23. 25-hydroxy Vitamin D3
24. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
25. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
26. U-32070e
27. U 32070 E
28. 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / Calcidiol
29. 25-hydroxycholescalciferol
30. Calcifediolum [inn-latin]
31. Rovimix Hy-d
32. (1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
33. (3b,5z,7e)- 9,10-secocholesta-5,7,10(19)-triene-3,25-diol
34. Vitamin D, 25-hydroxy-
35. Hy-d
36. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
37. 36149-00-5
38. 25-(oh)vitamin D3
39. 5,6-trans-25-hydroxycholescalciferol
40. Unii-t0wxw8f54e
41. Ryaldee
42. Bml2-e02
43. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
44. 25(oh)d3
45. Einecs 242-990-9
46. Mfcd00867077
47. U 32070e
48. Calcifediol [mi]
49. (5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
50. 5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
51. Spectrum5_001931
52. Dsstox_cid_2721
53. 25-hydroxy-cholecalciferol
54. Calcifediol,anhydrous
55. Schembl3296
56. Chembl1040
57. Dsstox_rid_76699
58. Dsstox_gsid_22721
59. Bspbio_001411
60. Calcifediol, Anhydrous
61. (3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
62. Gtpl6921
63. Dtxsid0022721
64. Chebi:94743
65. Amy2863
66. Bcpp000306
67. Dm100
68. Hms1361g13
69. Hms1791g13
70. Hms1989g13
71. Hms2089l21
72. Hms3402g13
73. 64719-49-9
74. Act06833
75. Zinc4474414
76. Tox21_111987
77. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
78. 9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-
79. Bdbm50521013
80. Calcifediol,anhydrous [vandf]
81. Lmst03020246
82. S1469
83. Akos015965097
84. Bcp9000472
85. Ccg-268657
86. Cs-0800
87. Db00146
88. Idi1_033881
89. Ncgc00161326-01
90. Ac-31367
91. Hy-32351
92. Cas-19356-17-3
93. 25-hydroxycholecalciferol, >=98% (hplc)
94. C01561
95. Ab01275461-01
96. Ab01275461_02
97. 356c173
98. A923587
99. Q139307
100. Sr-05000001468
101. Sr-05000001468-1
102. W-201718
103. 25-hydroxyvitamin D3 Monohydrate, >=99.0% (hplc)
104. 9,10-secocholesta-5,7,10(19)-triene-3b,25-diol
105. Brd-k77175907-001-01-5
106. B91135ec-8937-4d8b-a533-ccd82f33c1b0
107. Calcifediol, European Pharmacopoeia (ep) Reference Standard
108. (5e,7e)-9,10-secocholesta-5,7,10(19)-triene-3beta,25-diol
109. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, 98% (cp)
110. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, 98% (cp)
111. 25-hydroxyvitamin D3 Solution, 50 Mug/ml In Ethanol, 98% (cp)
112. Calcifediol, United States Pharmacopeia (usp) Reference Standard
113. (3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol
114. (5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol Monohydrate
115. 9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-
116. (?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol
117. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol
118. (s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol
119. 1h-indene-1-pentanol, Octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-
120. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
121. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 400.6 g/mol |
|---|---|
| Molecular Formula | C27H44O2 |
| XLogP3 | 6.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 6 |
| Exact Mass | 400.334130642 g/mol |
| Monoisotopic Mass | 400.334130642 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 655 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
Treatment of secondary hyperparathyroidism (SHPT)
Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
A - Alimentary tract and metabolism
A11 - Vitamins
A11C - Vitamin a and d, incl. combinations of the two
A11CC - Vitamin d and analogues
A11CC06 - Calcifediol
H - Systemic hormonal preparations, excl. sex hormones and insulins
H05 - Calcium homeostasis
H05B - Anti-parathyroid agents
H05BX - Other anti-parathyroid agents
H05BX05 - Calcifediol
Absorption
Readily absorbed.
Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.
288 hours
Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15564
Submission : 2001-08-02
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-07-28
Pay. Date : 2016-07-08
DMF Number : 21963
Submission : 2008-09-05
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33640
Submission : 2019-05-03
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12386
Submission : 1997-02-27
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 1998-059 - Rev 09
Status : Valid
Issue Date : 2024-12-02
Type : Chemical and TSE
Substance Number : 1295

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2019-163 - Rev 03
Status : Valid
Issue Date : 2025-07-31
Type : Chemical
Substance Number : 1295

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2015-359 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2022-08-09
Type : Chemical
Substance Number : 1295

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2022-335 - Rev 00
Status : Valid
Issue Date : 2022-11-29
Type : Chemical
Substance Number : 1295

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC Package Code : 45408-002
Start Marketing Date : 2012-08-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Enaltec, founded in 2006, specializes in developing and manufacturing complex, small-volume, technology-driven APIs at competitive prices, leveraging the India advantage for global...
About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...

About the Company : DISHMAN Netherlands is located in Veenendaal in the middle of the Netherlands. We are active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol a...

About the Company : DongWha is the company that "serves customers by making good medicines and is managed with the rewards generated by benefits of good medicines." Under its corporate philosophy that...

About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...

About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...

About the Company : Jiangxi Tianxin Pharmaceutical Co.,Ltd. was established in 2004, it is hi-tech enterprise of China, located in Le'anjiang Industrial Zone, Leping, China and close to national highw...

About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: VFMCRP
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : VFMCRP
Deal Size : Inapplicable
Deal Type : Inapplicable
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact iPTH.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Undisclosed
Deal Type : Termination
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Details : Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 15, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients
Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 01, 2020

Details:
Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Junta de Andalucía | Dynamic Solutions | Faes Farma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2020

Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Junta de Andalucía | Dynamic Solutions | Faes Farma
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 29, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperparathyroidism, Secondary-associated with Renal Insufficiency, Chronic.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperparathyroidism, Secondary-associated with Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 26, 2018

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
Calcifediol - reference spectrum
CAS Number : n/a
Quantity Per Vial : n/a
Sale Unit : 1
Order Code : C0166001
Batch No : 1
Price (€) : 79
Storage :

CAS Number : 63283-36-3
Quantity Per Vial : 5 mg
Sale Unit : 1
Order Code : C0166000
Batch No : 6
Price (€) : 150
Storage : -20°C ± 5°C

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 63283-36-3
Quantity Per Vial : 75
Sale Unit : mg
Price : $715.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1086108 / R03160

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
87
PharmaCompass offers a list of Calcifediol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Calcifediol manufacturer or Calcifediol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcifediol manufacturer or Calcifediol supplier.
PharmaCompass also assists you with knowing the Calcifediol API Price utilized in the formulation of products. Calcifediol API Price is not always fixed or binding as the Calcifediol Price is obtained through a variety of data sources. The Calcifediol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Hy-D manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hy-D, including repackagers and relabelers. The FDA regulates Hy-D manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hy-D API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hy-D manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hy-D supplier is an individual or a company that provides Hy-D active pharmaceutical ingredient (API) or Hy-D finished formulations upon request. The Hy-D suppliers may include Hy-D API manufacturers, exporters, distributors and traders.
click here to find a list of Hy-D suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hy-D DMF (Drug Master File) is a document detailing the whole manufacturing process of Hy-D active pharmaceutical ingredient (API) in detail. Different forms of Hy-D DMFs exist exist since differing nations have different regulations, such as Hy-D USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hy-D DMF submitted to regulatory agencies in the US is known as a USDMF. Hy-D USDMF includes data on Hy-D's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hy-D USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hy-D suppliers with USDMF on PharmaCompass.
A Hy-D CEP of the European Pharmacopoeia monograph is often referred to as a Hy-D Certificate of Suitability (COS). The purpose of a Hy-D CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hy-D EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hy-D to their clients by showing that a Hy-D CEP has been issued for it. The manufacturer submits a Hy-D CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hy-D CEP holder for the record. Additionally, the data presented in the Hy-D CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hy-D DMF.
A Hy-D CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hy-D CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hy-D suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hy-D as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hy-D API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hy-D as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hy-D and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hy-D NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hy-D suppliers with NDC on PharmaCompass.
Hy-D Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hy-D GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hy-D GMP manufacturer or Hy-D GMP API supplier for your needs.
A Hy-D CoA (Certificate of Analysis) is a formal document that attests to Hy-D's compliance with Hy-D specifications and serves as a tool for batch-level quality control.
Hy-D CoA mostly includes findings from lab analyses of a specific batch. For each Hy-D CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hy-D may be tested according to a variety of international standards, such as European Pharmacopoeia (Hy-D EP), Hy-D JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hy-D USP).